A registration-directed clinical trial of selinexor [KPT 330] in patients with squamous cell cancers of the head & neck, lung, or oesophagus
Latest Information Update: 16 May 2014
Price :
$35 *
At a glance
- Drugs Selinexor (Primary)
- Indications Head and neck cancer; Lung cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 16 May 2014 New trial record